Ms Pip Marks

Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1

Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020

Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-017-2517-3

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4

Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, vol. 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007

Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, vol. 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844

Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0150655

Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, vol. 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003

Giarda P; Avihingsanon A; Sasadeusz J; Audsley J; Marks P; Matthews G; Ruxrungtham K; Lewin SR; Crane M, 2014, 'CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy', Antiviral Therapy, vol. 19, pp. 429 - 433, http://dx.doi.org/10.3851/IMP2720

Treloar C; Rance J; Haber P; Bath N; Day C; Dore G; Grebely J; Honey C; Krahn M; Lodge M, 2014, 'How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting', International Journal of Drug Policy, vol. 25, pp. 865 - 870, http://dx.doi.org/10.1016/j.drugpo.2014.01.011

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC³ Study', Journal of Clinical Virology, vol. 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027

Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', Journal of Nursing Administration, vol. 44, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150

Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', European Journal of Gastroenterology and Hepatology, vol. 26, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150

Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, vol. 31, pp. 33 - 33, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000311236700104&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Avihingsanon A; Matthews GV; Lewin SR; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Dore GJ; Ruxrungtham K, 2012, 'Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand', AIDS Research and Therapy, vol. 9, http://dx.doi.org/10.1186/1742-6405-9-6

Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M, 2012, 'Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology (Australia), vol. 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Crawford DHG; Dore GJ; Sievert W; Cheng WSC; Weltman M; McCaughan G; Rawlinson W; Marks PS; Yoshihara M; Rizkalla B, 2012, 'Early on-treatment viral load and baseline METAVIR score: Improved prediction of sustained virological response in HCV genotype 1 patients', Antiviral Therapy, vol. 17, pp. 849 - 854, http://dx.doi.org/10.3851/IMP2104

Matthews GV; Pham ST; Hellard M; Grebely J; Zhang L; Oon A; Marks P; Van Beek I; Rawlinson W; Kaldor JM, 2011, 'Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C', Clinical Infectious Diseases, vol. 52, pp. 803 - 811, http://dx.doi.org/10.1093/cid/ciq200

Dore GJ; Hellard M; Matthews GV; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G, 2010, 'Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection', Gastroenterology, vol. 138, http://dx.doi.org/10.1053/j.gastro.2009.09.019

Grebely J; Petoumenos K; Matthews GV; Haber P; Marks P; Lloyd AR; Kaldor JM; Dore GJ; Hellard M, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC study', Drug and Alcohol Dependence, vol. 107, pp. 244 - 249, http://dx.doi.org/10.1016/j.drugalcdep.2009.09.015

Grebely J; Petoumenos K; Hellard M; Matthews GV; Suppiah V; Applegate T; Yeung B; Marks P; Rawlinson W; Lloyd AR, 2010, 'Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection', Hepatology, vol. 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850

Cheng WSC; Roberts SK; McCaughan G; Sievert W; Weltman M; Crawford D; Rawlinson W; Marks PS; Thommes J; Rizkalla B, 2010, 'Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing', Journal of Hepatology, vol. 53, pp. 616 - 623, http://dx.doi.org/10.1016/j.jhep.2010.04.024

Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, vol. 28, pp. A27 - A27, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews GV; Seaberg E; Dore GJ; Bowden S; Lewin SR; Sasadeusz J; Marks P; Goodman Z; Philp FH; Tang Y, 2009, 'Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals', AIDS, vol. 23, pp. 1707 - 1715, http://dx.doi.org/10.1097/QAD.0b013e32832b43f2

Matthews GV; Hellard M; Haber P; Yeung B; Marks P; Baker D; McCaughan G; Sasadeusz J; White P; Rawlinson W, 2009, 'Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C', Clinical Infectious Diseases, vol. 48, pp. 650 - 658, http://dx.doi.org/10.1086/596770

Lewin SR; Ribiero RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ, 2009, 'Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy', Hepatology, vol. 49, pp. 1113 - 1121, http://dx.doi.org/10.1002/hep.22754

Chang JJ; Sirivichayakul S; Avihingsanon A; Thompson AJV; Revill P; Iser D; Slavin J; Buranapraditkun S; Marks P; Matthews G, 2009, 'Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection', Journal of Virology, vol. 83, pp. 7649 - 7658, http://dx.doi.org/10.1128/JVI.00183-09

Roberts SK; Weltman MD; Crawford DHG; McCaughan GW; Sievert W; Cheng WS; Rawlinson W; Desmond PV; Marks PS; Yoshihara M, 2009, 'Impact of high-dose peginterferon alfa-2a on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial', Hepatology, vol. 50, pp. 1045 - 1055, http://dx.doi.org/10.1002/hep.23130

Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S, 2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand', Hepatology, vol. 48, pp. -1069, http://dx.doi.org/10.1002/hep.22462

Burmeister B; Smithers M; Gebski V; Denham J; Devitt P; Ackland S; Findlay M; Dhillon H; Stockler M; Coates A, 2005, 'Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial', Lancet Oncology, vol. 6, pp. 659 - 668, http://dx.doi.org/10.1016/S1470-2045(05)70288-6

Matthews GV; Hellard M; Haber P; Yeung B; Marks P; Sasadcusz J; Baker D; McCaughan G; White P; Rawlinson W, 2008, 'Frequency of RVR and its utility as a predictor of treatment outcome in individuals treated within the Australian Trial in Acute Hepatitis c (ATAHC)', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Milan, ITALY, pp. S303 - S303, presented at 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Milan, ITALY, 23 - 27 April 2008, http://dx.doi.org/10.1016/S0168-8278(08)60812-0

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks P; Revill PA; Ayres A; Bow-den S; Locarnini S; Thio CL, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in HEPATOLOGY, JOHN WILEY & SONS INC, San Francisco, CA, pp. 712A - 713A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San Francisco, CA, 31 October - 04 November 2008, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401290&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Jones T; Marks P; Connelly C; Fragomeli V; Warner S; Walker P; Ferguson C; Dore GJ, 2008, 'Predictors of HCV treatment uptake and clinical trial participation among patients newly referred for HCV infection: the HCV clinical audit study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A241 - A241, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100133&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews GV; White PA; Hellard M; Grebely J; Marks P; Yeung B; Kaldor JM; Lloyd A; Danta M; Dore GJ, 2008, 'Evidence of sexual transmission of hepatitis C virus infection among HIV-positive men who have sex with men in the Australian trial in acute hepatitis C (ATAHC) study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A365 - A366, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews G; Grebely J; White PA; Renkin MK; Marks P; Ffrench RA; Rawlinson W; Kaldor J; Hellard M; Lloyd AR, 2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in HEPATOLOGY, JOHN WILEY & SONS INC, San Francisco, CA, pp. 1130A - 1131A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San Francisco, CA, 31 October - 04 November 2008, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757402521&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Hellard M; Matthews GV; Petoumenos K; Grebely J; Haber P; Van Beek I; Marks P; Lloyd A; Kaldor J; Dore GJ, 2008, 'Factors associated with uptake of treatment for acute and early chronic hepatitis C virus infection', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A344 - A344, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks PB; Revill P; Ayres A; Bow-den S; Locarnini S; Thio C, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology, 01 January 2008

Crawford D; Robertson SL; Weltman MD; Cheng W; Sievert W; McCaughan G; Desmond PV; Alston A; DePamphilis J; Marks PB, 2008, 'Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: The CHARIOT study', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S290 - S291, presented at Journal of Hepatology, 01 January 2008